BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
- Product
- In this atlas
Overview
Technical summary
Drugs@FDA application NDA208374. Original approval 2017-12-21. No efficacy supplement approvals are on record. 2 products listed.
Trials at a glance
No registry trial in this atlas names this product.
- Regulatory decisions
- 1
Product details
- Type
- Medicine
- Model or formulation
- Dosage forms in the registry record: SOLUTION
- Version
- Not stated in the openFDA record
Intended-use sources
No intended-use source is recorded.
The registry's words
Labels as the registry gives them, not rewritten.
- Application
- NDA208374
- Brand name
- BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
- Applicant
- BAXTER HLTHCARE CORP
- Active ingredient
- BIVALIRUDIN
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
Claims and evidence
Context FDA record read by the openFDA feed
- Recipient
- Recipient not specified
- Population
- Not stated in the openFDA record
- Care setting
- Not stated in the openFDA record
- Geography
- United States (a decision by the US Food and Drug Administration)
- Life stage
- Not stated in the openFDA record
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
- Included
- None stated
- Excluded
- None stated
FDA records an approval of NDA208374 on 2017-12-21.
Applies to Recipient not specified FDA record read by the openFDA feed
- Certainty method
- Not assessed
- Limitations
- Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked
- Not recorded
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Drugs@FDA application NDA208374 (openFDA record)
- Locator
- submissions[0].submission_status_date
- How it applies
- The decision date as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA208374 (openFDA record)
- Locator
- application_number
- How it applies
- The registry number of the record.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
-
Supports Drugs@FDA application NDA208374 (openFDA record)
- Locator
- submissions[0].submission_status
- How it applies
- The decision status as the record writes it.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for this product.
No label from the application holder was found in the openFDA label dataset for application NDA208374. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this product, oldest first. Each links to its full record.
Authorization
Regulatory decision: BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
- Not stated in the openFDA record
- Not stated in the openFDA record
- United States (a decision by the US Food and Drug Administration)
- Not stated in the openFDA record
- Gestational age Not reported
- Postnatal age Not reported
- Authority
- U.S. Food and Drug Administration
- Decision
- Approval,
- Pathway
- NDA
- Submission
NDA208374- Jurisdictions
- United States
- Product version
- Original application
- Indication
- Not stated in the openFDA record
- Basis
- FDA records an approval of NDA208374 on 2017-12-21.
Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
Record details
- Record id
cardio:fdaprod-nda208374- Content hash
6fda3860c8a8b7d2726419cfe1d250ac4e46ce85f3f2cff279566dc3245fd6bf